Skip to main content

Advertisement

SpringerLink
Log in

The rhPTH treatment elevates plasma secreted protein acidic and rich in cysteine levels in patients with osteoporosis

  • Short Communication
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

The secreted protein acidic and rich in cysteine (SPARC), also known as osteonectin, plays an important role in osteoblast formation, maturation, and survival. Here, we report the effects of recombinant human parathyroid hormone (1-34) [rhPTH (1-34)], a bone formation-stimulating agent, and elcatonin on plasma SPARC levels in patients with osteoporosis. The rhPTH (1-34) treatment significantly increased plasma SPARC levels, and the change of plasma SPARC correlated positively with changes of lumbar bone mineral density (BMD) at L2–L4. These results unveil that SPARC may be a novel marker related to the regulation of bone formation.

Introduction

rhPTH (1-34) is known to influence osteoclast maturation and activity through modulation of osteoblast-derived cytokines. SPARC is the most abundant noncollagenous extracellular matrix protein in the bone. So far, however, no study has reported the effects of rhPTH (1-34) administration on plasma SPARC levels in patients with osteoporosis. The purpose of this study was to compare the response of SPARC and BMD to rhPTH (1-34) and elcatonin in postmenopausal women with osteoporosis.

Methods

Women were randomized to either once-daily subcutaneous injection of rhPTH (1-34) (20 μg, N = 89) or once-weekly intramuscular injection of elcatonin (200 U, N = 35) for 12 months. Plasma biochemical markers of bone turnover and BMD were measured at baseline, 6 and 12 months after treatment.

Results

At baseline, plasma SPARC levels correlated positively with lumbar spine BMD in all patients (r = 0.45, p = 0.001). Compared with baseline, at 12 months, rhPTH (1-34) significantly increased lumbar spine BMD and plasma SPARC levels (p = 0.008 and p = 0.001, respectively), whereas elcatonin was ineffective. More importantly, the changes of plasma SPARC correlated positively with changes of lumbar BMD at L2–L4 (r = 0.47, p = 0.001) in the rhPTH (1-34)-treated group, but not in the elcatonin group.

Conclusion

The increase in plasma SPARC levels during the rhPTH (1-34) treatment may have contributed to the anabolic effect on bone formation, and SPARC may be a novel marker related to the regulation of bone formation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Meunier PJ, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S, Sarkar S, Liu T, Wong M, Draper MW (1999) Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group. Osteoporos Int 10:330–336

    Article  PubMed  CAS  Google Scholar 

  2. Riggs BL, Melton LJ III (1995) The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17:505S–511S

    Article  PubMed  CAS  Google Scholar 

  3. Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441

    Article  PubMed  CAS  Google Scholar 

  4. Reeve J, Bradbeer JN, Arlot M et al (1991) hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses. Osteoporos Int 1:162–170

    Article  PubMed  CAS  Google Scholar 

  5. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F (1997) Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550–555

    Article  PubMed  CAS  Google Scholar 

  6. Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL (2003) Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18:539–543

    Article  PubMed  CAS  Google Scholar 

  7. Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R (2001) Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 16:925–931

    Article  PubMed  CAS  Google Scholar 

  8. Pettway GJ, Meganck JA, Koh AJ, Keller ET, Goldstein SA, McCauley LK (2008) Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone 42:806–818

    Article  PubMed  CAS  Google Scholar 

  9. Bikle DD, Sakata T, Leary C, Elalieh H, Ginzinger D, Rosen CJ, Beamer W, Majumdar S, Halloran BP (2002) Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res 17:1570–1578

    Article  PubMed  CAS  Google Scholar 

  10. Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK, Weinstein RS, O'Brien CA, Manolagas SC, Jilka RL (2003) Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 278:50259–50272

    Article  PubMed  CAS  Google Scholar 

  11. Brixen KT, Christensen PM, Ejersted C, Langdahl BL (2004) Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis. Basic Clin Pharmacol Toxicol 94:260–270

    PubMed  CAS  Google Scholar 

  12. Bradshaw AD, Sage EH (2001) SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 107:1049–1054

    Article  PubMed  CAS  Google Scholar 

  13. Delany AM, Kalajzic I, Bradshaw AD, Sage EH, Canalis E (2003) Osteonectin-null mutation compromises osteoblast formation, maturation, and survival. Endocrinology 144:2588–2596

    Article  PubMed  CAS  Google Scholar 

  14. Delany AM, Amling M, Priemel M, Howe C, Baron R, Canalis E (2000) Osteopenia and decreased bone formation in osteonectin-deficient mice. J Clin Invest 105:915–923

    Article  PubMed  CAS  Google Scholar 

  15. Boskey AL, Moore DJ, Amling M, Canalis E, Delany AM (2003) Infrared analysis of the mineral and matrix in bones of osteonectin-null mice and their wild-type controls. J Bone Miner Res 18:1005–1011

    Article  PubMed  CAS  Google Scholar 

  16. Machado do Reis L, Kessler CB, Adams DJ, Lorenzo J, Jorgetti V, Delany AM (2008) Accentuated osteoclastic response to parathyroid hormone undermines bone mass acquisition in osteonectin-null mice. Bone 43:264–273

    Article  PubMed  CAS  Google Scholar 

  17. Hwang JS, Tu ST, Yang TS, Chen JF, Wang CJ, Tsai KS (2006) Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int 17:373–378

    Article  PubMed  CAS  Google Scholar 

  18. Zhang XZ, Wang B, Yang J et al (2009) A randomized, multicenter controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with elcatonin in postmenopausal women with osteoporosis in China. Chin Med J (Engl) 122:2933–2938

    CAS  Google Scholar 

  19. Lindsay R, Miller P, Pohl G, Glass EV, Chen P, Krege JH (2009) Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20:943-948

  20. Riggs BL, Melton LJ, Robb RA, Camp JJ, Atkinson EJ, McDaniel L, Amin S, Rouleau PA, Khosla S (2008) A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res 23:205–214

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (30871199, 30771037, 30971388, and 81070640).

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Endocrinology, the Second Affiliated Hospital, Chongqing Medical University, 400010, Chongqing, China

    L. Zhang, M. Yang, K. Xu & G. Yang

  2. Department of Clinical Biochemistry and the Key Laboratory of Laboratory Medical Diagnostics in the Ministry of Education, Chongqing Medical University, 400010, Chongqing, China

    L. Li

  3. The Division of Endocrinology/Diabetes/Metabolism and the Clinical Research Center, Temple University School of Medicine, Philadelphia, PA, USA

    G. Boden

Authors
  1. L. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Boden
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to K. Xu or G. Yang.

Additional information

Trial registration: ChiCTR-TRC-11001331

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Fig. 1

Relationship between fasting plasma SPARC levels and BMD. A Correlation of plasma SPARC levels with lumbar spine BMD at baseline; B correlation between the changes of plasma SPARC and L2–4 BMD at month 12 in the rhPTH (1-34) group; C correlation between the changes of plasma SPARC and L2–4 BMD at month 12 in the elcatonin group (JPEG 21 kb)

High Resolution Image (TIFF 134 kb)

Supplementary Table 1

Baseline characteristics in two groups (DOC 83 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, L., Li, L., Yang, M. et al. The rhPTH treatment elevates plasma secreted protein acidic and rich in cysteine levels in patients with osteoporosis. Osteoporos Int 24, 1107–1112 (2013). https://doi.org/10.1007/s00198-012-1956-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-012-1956-3

Keywords

Search

Navigation